| 1 |
Danson, S., Ferry, D., Alakhov, V., Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., Ranson, M., 2004. Phase I dose escalation and pharmacokinetic study of pluronicpolymer-bound doxorubicin (SP1049C) in patients with advanced cancer.
Br. J. Cancer. 90, 2085-2091.
DOI
|
| 2 |
De Jong, W.H., Borm, P.J., 2008. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomedicine 3(2), 133-149.
|
| 3 |
Ducry, L., Stump, B., 2010. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem. 21, 5-13.
DOI
|
| 4 |
Ferrari, M., 2005. Cancer nanotechnology: opportunities and challenges.
Nat. Rev. Cancer 5, 161-171.
DOI
|
| 5 |
Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., Barenholz, Y., 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res. 54, 987-992.
|
| 6 |
Alivisatos, P., 2004. The use of nanocrystals in biological detection.
Nat. Biotechnol. 22, 47-52.
DOI
|
| 7 |
Allen, T.M., 2002. Ligand-targeted therapeutics in anticancer therapy.
Nat. Rev. Cancer 2(10), 750-763.
DOI
|
| 8 |
Batist, G., 2007. Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol. 7, 72-74.
DOI
|
| 9 |
Batist, G., Gelmon, K.A., Chi, K.N., Miller, W.H. Jr., Chia, S.K., Mayer, L.D., Swenson, C.E., Janoff, A.S., Louie, A.C., 2009. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15, 692-700.
DOI
|
| 10 |
Black, K.C., Kirkpatrick, N.D., Troutman, T.S., Xu, L., Vagner, J., Gillies, R. J., Barton, J.K., Utzinger, U., and Romanowski, M., 2008. Gold nanorods targeted to delta opioid receptor: plasmon-resonant contrast and photothermal agents. Mol. Imaging 7(1), 50-57.
|
| 11 |
Cardinal, J., Klune, J.R., Chory, E., Jeyabalan, G., Kanzius, J.S., Nalesnik, M., Geller, D. A., 2008. Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery 144, 125-132.
DOI
|
| 12 |
Valle, J.W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E.K., Ranson,
M., 2010. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Invest. New Drugs, Published online, DOI 10.1007/s10637-010-9399-1.
DOI
|
| 13 |
Smith, B.R., Cheng, Z., De, A., Koh, A.L., Sinclair, R., Gambhir, S.S., 2008, Real-Time Intravital Imaging of RGD-Quantum Dot Binding to Luminal Endothelium in Mouse Tumor Neovasculature. Nano. Lett. 8(9), 2599-2606.
DOI
|
| 14 |
Sutton, D., Nasongkla, N., Blanco, E., Gao, J., 2007. Functionalized
micellar systems for cancer targeted drug delivery. Pharm. Res. 24, 1029-1046.
DOI
|
| 15 |
Tassinari, O.W., Caiazzo, R.J., Jr., Ehrlich, J.R., and Liu, B.C., 2008. Identifying autoantigens as theranostic targets: antigen arrays and immunoproteomics approaches. Curr. Opin. Mol. Ther. 10(2), 107-115.
|
| 16 |
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D.A., Torchilin, V.P., and Jain, R.K., 1995. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756.
|
| 17 |
Santra, S., Kaittanis, C., Grimm, J., and Perez, J. M., 2009. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 5(16), 1862-1868.
DOI
ScienceOn
|
| 18 |
Richter, H., Kettering, M., Wiekhorst, F., Steinhoff, U., Hilger, I., Trahms, L., 2010. Magnetorelaxometry for localization and quantification of magnetic nanoparticles for thermal ablation studies. Phys. Med. Biol. 55, 623-633.
DOI
|
| 19 |
Sahoo, S.K., Ma,W., Labhasetwar,V., 2004. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112(2), 335-340.
DOI
|
| 20 |
Sakamoto, J., Annapragada, A., Decuzzi, P., Ferrari, M., 2007. Antibiological barrier nanovector technology for cancer applications.
Expert Opin. Drug Deliv. 4, 359-369.
DOI
|
| 21 |
Santra, S., Liesenfeld, B., Dutta, D., Chatel, D., Batich, C. D., Tan, W., Moudgil, B. M., Mericle, R. A., 2005. Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J. Nanosci. Nanotechnol. 5(6), 899-904.
DOI
|
| 22 |
Matsumura, Y., 2008. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev. 60, 899-914.
DOI
|
| 23 |
Seymour, L.W., Ferry, D.R., Kerr, D.J., Rea, D., Whitlock, M., Poyner, R., Boivin, C., Hesslewood, S., Twelves, C., Blackie, R., Schatzlein, A., Jodrell, D., Bissett, D., Calvert, H., Lind, M., Robbins, A., Burtles, S., Duncan, R., Cassidy, J., 2009. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 34, 1629-1636.
|
| 24 |
Shenoi, M.M., Anderson, J., Bischof, J.C., 2009. Nanoparticle enhanced thermal therapies. Conf Proc IEEE Eng. Med. Biol. Soc. 2009, 1979-1982.
|
| 25 |
Siegal, T., Horowitz, A., Gabizon, A., 1995. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 83, 1029-1037.
DOI
|
| 26 |
Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., Sundaresan, G., Wu, A.M., Gambhir, S.S., Weiss, S., 2005. Quantum dots for live cells, in vivo imaging, and diagnostics.
Science 307, 538-544
DOI
|
| 27 |
Misra, R., Acharya, S., Sahoo, S.K., 2010. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discovery Today 15, 19-20.
|
| 28 |
Mross, K., Niemann, B., Massing, U., Drevs, J., Unger, C., Bhamra, R., 2004. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother. Pharmacol. 54, 514-524.
DOI
|
| 29 |
Nie, S. Nie, S., Xing, Y., Kim, G.J., Simons, J.W., 2007., Nanotechnology
applications in cancer. Annu. Rev. Biomed. Eng. 9, 257-288.
DOI
|
| 30 |
Park, J.W., Benz, C.C., and Martin, F.J., 2004. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin. Oncol. 31(6 Suppl 13), 196-205.
DOI
|
| 31 |
Kirpotin, D.B., Drummond, D.C., Shao, Y., Shalaby, M.R., Hong, K., Nielsen, U.B., Marks, J. D., Benz, C.C., and Park, J.W., 2006 Antibody targeting of longcirculating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740.
DOI
|
| 32 |
Pautler, M., Brenner, S., 2010. Nanotechnology and human health: risks and Benefits. Int. J. of Nanomedicine 5, 803-809.
|
| 33 |
Puri, A., Kramer-Marek, G., Campbell-Massa, R., Yavlovich, A., Tele, S.C., Lee S.B., Clogston, J.D., Patri, A.K., Blumenthal, R., Capala, J., 2008. HER2-specific affibody conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J. Liposome Res. 18, 293-307.
DOI
|
| 34 |
Rahman, A.M., Yusuf, S., Ewer, M.S., 2007. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomedicine 2, 567-583.
|
| 35 |
Kong, G., Braun, R.D., Dewhirst, M.W., 2000. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440-4445.
|
| 36 |
Krishnan, S., Diagaradjane, P., Cho, S.H., 2010. Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int. J. Hyperthermia 26, 775-789.
DOI
|
| 37 |
Kumar, M., Yigit, M., Dai, G., Moore, A., Medarova, Z., 2010. Image-guided breast tumor therapy using a siRNA nanodrug. Cancer Res. 70,7553-7561.
DOI
|
| 38 |
Lammers, T., Hennink, W. E., and Storm,G., 2008. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99(3), 392-397.
DOI
|
| 39 |
Maeda, H., Matsumura, Y., 1989. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6(3), 193-210.
|
| 40 |
Maruyama, K., Unezaki, S., Yuda, T., Ishida, O., Takahashi, N., Suginaka, A., et al., 1994. Enhanced delivery and antitumor effect of doxorubicin encapsulated in long-circulating liposomes.
J. Liposome Res. 4, 143-165.
DOI
|
| 41 |
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada,
Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., Chin, K., Baba, S., Yamao, T., Kannami, A., Takamatsu, Y., Ito, K., Takahashi, K., 2004a. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15, 517-525.
DOI
|
| 42 |
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., Watanabe, N., 2004b. Phase I clinical trial and pharmacokinetic evaluations of NK911, a micelle-encapsulated doxorubicin.
Br. J. Cancer 91, 1775-1781.
DOI
|
| 43 |
Gao, X., Yang, L., Petros, J.A., Marshall, F.F., Simons, J.W., Nie, S., 2005. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 63-72.
DOI
|
| 44 |
Gaster, R.S., Hall, D.A., Nielsen, C.H., Osterfeld, S.J., Yu, H., Mach, K.E., Wilson, R.J., Murmann. B., Liao, J.C., Gambhir, S.S., Wang, S.X., 2009. Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat. Med. 15, 1327-1332.
DOI
|
| 45 |
Grobmyer, S.R., Iwakuma, N., Sharma, P., Moudgil B.M., 2010. What is cancer nanotechnology? Methods Mol. Biol. 624, 1-9.
DOI
|
| 46 |
Grodzinski, P. Silver, M., Molnar, L.K., 2006. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev. Mol. Diagn. 6, 307-318.
DOI
|
| 47 |
Hilger, I., Hergt, R., Kaiser, W.A., 2005. Use of magnetic nanoparticle
heating in the treatment of breast cancer. IEE, Proc. Nanobiotechnol. 152, 33-39.
DOI
|
| 48 |
Jain, K.K., 2005. Role of nanobiotechnology in developing personalized
medicine for cancer. Technol. Cancer Res. Treat. 4, 407-416.
|
| 49 |
Huff, T.B., Tong, L., Zhao, Y., Hansen, M.N., Cheng, J.X., Wei, A., 2007. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine (Lond) 2, 125-132.
DOI
|
| 50 |
Ito, A., Kuga, Y., Honda, H., Kikkawa, H., Horiuchi, A., Watanabe, Y., Kobayashi, T., 2004. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett. 212, 167-175.
DOI
|
| 51 |
Jain, K.K., 2007. Applications of nanobiotechnology in clinical diagnostics. Clin. Chem. 53, 2002-2009.
DOI
|
| 52 |
Jain, K.K., 2010. Advances in the field of nanooncology. BMC Medicine 8:83.
DOI
|
| 53 |
Carter, P.J., Senter, P.D., 2008. Antibody-drug conjugates for cancer therapy. Cancer J. 14, 154-169.
DOI
|
| 54 |
Chia, S., Clemons, M., Martin, L.A., Rodger, S.A., Gelmon, K., Pond, G.R., Panasci, L., 2006. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J. Clin. Oncol. 24, 2773-2778.
DOI
|
| 55 |
Cho, K., Wang, X., Nie, S., Chen, Z.G., and Shin, D.M., 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14(5), 1310-1316.
DOI
|
| 56 |
Choi, J.S., Jun, Y.W., Yeon, S.I., Kim, H.C., Shin, J. S., Cheon, J., 2006. Biocompatible heterostructured nanoparticles for multimodal biological detection. J. Am. Chem. Soc. 128, 15982-15983.
DOI
|
| 57 |
Cuenca, A.G., Jiang, H., Hochwald, S.N., Delano, M., Cance, W.G., Grobmyer, S.R., 2006. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107, 459-466.
DOI
|
webmaster
